缅北禁地

缅北禁地 Appoints Dr. Matthew Sleeman as Chief Scientific Officer

缅北禁地 Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

缅北禁地 Expands Leadership Team and Appoints Head of Development and General Counsel

缅北禁地 Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

缅北禁地 Awarded Significant Grant from Innovate UK鈥檚 Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

缅北禁地 Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

缅北禁地鈥� M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting

缅北禁地 to Present at Evercore ISI 2024 Emerging Biotech Conference

缅北禁地 Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program

缅北禁地 and VIB enter into an exclusive partnership in oncology

缅北禁地 appoints Prof. Ton Logtenberg as Chair

缅北禁地 founding investigator Prof. David A. Tuveson elected to US National Academy of Medicine

Fierce Biotech names 缅北禁地 as one of its 鈥淔ierce 15鈥� Biotech Companies of 2021

缅北禁地 Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures

缅北禁地 announces collaboration with Janssen, focused on the discovery of novel fibroblast targets for the treatment of inflammatory disease

缅北禁地 launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer

缅北禁地 congratulates Founder Professor David A. Tuveson upon his appointment as 2021 President of The American Association for Cancer Research